Skip to main content
IC
BeiGene, Ltd. (HKG:6160)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
134.10
+6.30 (4.93%)
May 13, 2025, 1:45 PM HKT

BeiGene Revenue

BeiGene had revenue of $1.12B USD in the quarter ending March 31, 2025, with 48.64% growth. This brings the company's revenue in the last twelve months to $4.18B, up 51.16% year-over-year. In the year 2024, BeiGene had annual revenue of $3.81B with 54.96% growth.

Revenue (ttm)
$4.18B
Revenue Growth
+51.16%
P/S Ratio
6.04
Revenue / Employee
$379.62K
Employees
11,000
Market Cap
196.20B HKD

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20243.81B1.35B54.96%
Dec 31, 20232.46B1.04B73.65%
Dec 31, 20221.42B239.64M20.37%
Dec 31, 20211.18B867.41M280.83%
Dec 31, 2020308.87M-119.34M-27.87%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Hansoh Pharmaceutical Group Company 13.05B
JD Health International 61.89B
WuXi Biologics 19.87B
Innovent Biologics 10.03B
Alibaba Health Information Technology 31.39B
Akeso 2.26B
Sichuan Kelun-Biotech Biopharmaceutical 2.06B
Sino Biopharmaceutical 30.72B
Revenue Rankings

BeiGene News

More News